Paper Details

  1. Home
  2. Paper Details

Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.

Author: Di PerriG, EsserS, LelièvreJ-D, ParczewskiM, ShafranS D

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This study discusses the use of tenofovir alafenamide (TAF) as a safer alternative to tenofovir disoproxil fumarate (TDF) in antiretroviral therapy (ART) for HIV-infected patients. TAF has been shown to have improved renal and bone safety while maintaining efficacy, making it a preferred option for HIV patients, especially as the population ages and comorbidities become more common.
Paper Details　
Original Abstract of the Article :
Since the introduction of suppressive antiretroviral therapy (ART), HIV has become a chronic disease, with infected people in high-income countries approaching similar life expectancy to the general population. As this population ages, an increasing number of people with HIV are living with age-, tr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/hiv.12755

データ提供：米国国立医学図書館（NLM）

Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide

HIV research is like a vast desert, always seeking new oases of knowledge. This study, like a camel traversing a vast desert, delves into the crucial aspect of planning HIV therapy to prevent future comorbidities. This study explores the use of tenofovir alafenamide (TAF) as a potential solution to combat the rising incidence of comorbidities among aging individuals with HIV. It uses a thorough approach, comparing TAF to tenofovir disoproxil fumarate (TDF) and analyzing data from clinical trials and real-world studies.

TAF: a potential oasis in the desert of HIV treatment

This research reveals that TAF-based regimens offer a more favorable safety profile than TDF-containing regimens. This finding suggests that TAF could be a promising new approach to HIV treatment, potentially leading to a healthier and more comfortable life for individuals with HIV.

Finding the right path in the HIV treatment landscape

For those living with HIV, understanding the potential risks and benefits of different therapies is crucial. This study illuminates the potential of TAF in preventing comorbidities, empowering individuals to make informed decisions about their treatment. It's important to consult with healthcare professionals to determine the best treatment plan for each individual's specific needs.

Dr. Camel's Conclusion

This study, like a shimmering oasis in the desert of HIV research, brings hope for a more manageable future for individuals with HIV. The potential of TAF in preventing future comorbidities is an exciting development, paving the way for improved quality of life for those living with this chronic condition.
Date :
  1. Date Completed 2020-05-19
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

31099116

DOI: Digital Object Identifier

10.1111/hiv.12755

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.